Department of Cardiology, St Vincent's Hospital, Sydney; School of Clinical Medicine, Faculty of Health and Medicine, The University of New South Wales, Sydney, and The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia. Electronic address: http://www.twitter.com/drnikkibart.
Department of Cardiology, St Vincent's Hospital, Sydney; School of Clinical Medicine, Faculty of Health and Medicine, The University of New South Wales, Sydney, and The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia.
Heart Lung Circ. 2024 Apr;33(4):420-442. doi: 10.1016/j.hlc.2023.11.027. Epub 2024 Apr 2.
Over the past 5 years, early diagnosis of and new treatments for cardiac amyloidosis (CA) have emerged that hold promise for early intervention. These include non-invasive diagnostic tests and disease modifying therapies. Recently, CA has been one of the first types of cardiomyopathy to be treated with gene editing techniques. Although these therapies are not yet widely available to patients in Australia and New Zealand, this may change in the near future. Given the rapid pace with which this field is evolving, it is important to view these advances within the Australian and New Zealand context. This Consensus Statement aims to update the Australian and New Zealand general physician and cardiologist with regards to the diagnosis, investigations, and management of CA.
在过去的 5 年中，出现了一些针对心脏淀粉样变性（CA）的早期诊断和新治疗方法，这些方法有望进行早期干预。其中包括非侵入性诊断测试和疾病修饰疗法。最近，CA 是首批使用基因编辑技术治疗的心肌病之一。尽管这些疗法在澳大利亚和新西兰尚未广泛应用于患者，但这种情况可能在不久的将来会有所改变。鉴于该领域的发展速度如此之快，重要的是要从澳大利亚和新西兰的背景来看待这些进展。本共识声明旨在为澳大利亚和新西兰的全科医生和心脏病专家提供 CA 的诊断、检查和管理方面的最新信息。
